On 10-12 May 2021, the IMMUcan consortium presented an eTalk at the Association for Cancer Immunotherapy (CIMT) annual meeting. The CIMT annual meeting is the largest cancer immunotherapy event in Europe, connecting researchers on the state of the art in immunotherapy research and development.
IMMUcan’s presentation focuses on introducing the rationale of the project, key areas of work, and what IMMUcan hopes to achieve.
‘A better understanding of the tumor microenvironment (TME) is absolutely key to identify better biomarkers as well as develop new therapeutic options – there have been a number of efforts to better understand the TME, … but many of these efforts have been limited. IMMUcan has been formed to address [some of] these shortcomings,’ states Henoch Hong, Principal Scientist at Merck KGaA and IMMUcan project partner, in the eTalk presentation.
Watch it in full here: